Analyzing tumor DNA to predict response to cancer treatment in lung cancer patients
Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to Tyrosine Kinase Inhibitors in Patients With Advanced Non-small Cell Lung Cancer
This study is testing if measuring tumor DNA in the blood can help predict how well lung cancer patients respond to a specific treatment called Tyrosine Kinase Inhibitors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Gene Solutions Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ho Chi Minh City) |
| Trial ID | NCT06167460 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the dynamics of circulating tumor DNA (ctDNA) to predict and monitor the response to Tyrosine Kinase Inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). It aims to establish a relationship between ctDNA levels and clinical responses to TKI treatment, comparing ctDNA dynamics with traditional imaging methods. Patients will provide blood samples for ctDNA analysis at multiple time points, and their clinical outcomes will be monitored over a two-year period. The study will also assess the correlation between ctDNA changes and progression-free survival and overall survival rates.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with advanced non-small cell lung cancer who are eligible for TKI therapy and have not yet started treatment.
Not a fit: Patients who have already begun TKI or chemotherapy treatment prior to enrollment will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method to predict treatment responses in lung cancer patients, potentially leading to more personalized treatment strategies.
How similar studies have performed: Other studies have shown promise in using ctDNA analysis for monitoring treatment responses in various cancers, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients are diagnosed with advanced non-small cell lung cancer and indicated for TKI (first or second line). TKI combined with chemotherapy is allowed. * FFPE/FNA sample is available. * Compliant with treatment protocol. * Patients consented to participate in the study. Exclusion Criteria: * Patients already started TKI before enrollment. * Patients already started chemotherapy before enrollment. * Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol. * Patients did not agree to participate in the studies.
Where this trial is running
Ho Chi Minh City
- Medical Genetics Institute — Ho Chi Minh City, Vietnam (Recruiting)
Study contacts
- Principal investigator: Sinh D Nguyen, PhD — Mgi
- Study coordinator: Lan NL Tu, PhD
- Email: lantu@genesolutions.vn
- Phone: +84888843489
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.